Requires DOH to maintain emergency stockpile of insulin and authorizes dispensing of emergency supply of insulin to certain patients.
Impact
The legislation aims to enhance access to insulin for individuals with diabetes, particularly in urgent situations where they may run out of their prescribed supply. By establishing a stockpile and authorizing the DOH to dispense emergency insulin at a cost, the bill represents a significant proactive step towards minimizing potential healthcare crises related to insulin availability. This initiative is expected to positively impact the health outcomes of diabetics across New Jersey by reducing the risk of complications arising from insulin shortages.
Summary
Senate Bill S1820 mandates the New Jersey Department of Health (DOH) to maintain an emergency stockpile of insulin to assist residents who find themselves without their required supply before their next prescription can be filled. The bill specifies that the emergency stockpile must include at least the ten most common brands of insulin used in the state. Additionally, the DOH is tasked with monitoring the supply chain conditions and anticipated surges in demand for insulin to ensure that the stockpile meets current needs.
Contention
Despite its benefits, the bill may encounter skepticism regarding its logistical implementation and ongoing funding. Critics may point to concerns about the feasibility of managing the inventory effectively and ensuring that the right types and amounts of insulin are maintained in accordance with changing patient needs. Additionally, there could be debates around the adequacy of the insurance coverage provisions, as the bill mandates insurers to cover emergency supplies of insulin at least once every 12 months but does not stipulate funding mechanisms that guarantee sustainability for the program.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.